- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2023 · research · Advanced Clinical Research Award
Unraveling mechanisms of resistance to antibody drug conjugates in triple-negative breast cancer
Ana Garrido-Castro · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2023 · career development · Young Investigator Award
Understanding Circulating Tumor DNA at Critical Clinical Timepoints in Early-Stage Hormone Receptor-Positive Breast Cancer (CaTCH)
Marla Lipsyc-Sharf · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2023 · career development · Career Development Award
FhINCH: Fertility and sexual Health effects of Immune checkpoint inhibitors on young women with Non-small cell lung Cancer and Melanoma.
Narjust Florez · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2023 · research · Advanced Clinical Research Award
UBE2C as a biomarker of endocrine therapy resistance among Black women with estrogen receptor positive breast cancer
Veronica Jones · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2023 · career development · Young Investigator Award
Targeted DNA origami delivery of mRNA for in situ CAR-T cell generation
Elizabeth Carstens · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2023 · research · ASH Bridge Grant
ASH Bridge Grant 2023: Oreofe Odejide
Oreofe Odejide · Dana-Farber Cancer Institute · funded by American Society of Hematology
2023 · career development · Young Investigator Award
The Germline-Somatic Interaction in Young-Onset Lung Cancer
Jaclyn Lopiccolo · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2023 · career development · Career Development Award
Dissecting the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis for improved risk stratification and treatment
Riaz Gillani · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2023 · fellowship · AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Fellowship
Elucidating the unique biology of ILC and response to endocrine treatments
Capucine Héraud · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2023 · training · HIP Fellow Award
HIP Fellow Award 2023: Mwanasha Merrill
Mwanasha Merrill · Dana-Farber Cancer Institute · funded by American Society of Hematology
2023 · fellowship · ASH Research Training Award for Fellows (RTAF): First Year Awardees
ASH Research Training Award for Fellows (RTAF) 2023: Becky Zon
Becky Zon · Dana-Farber Cancer Institute · funded by American Society of Hematology
2023 · career development · Career Development Award
Developing a parent-driven social needs intervention for families of children with advanced cancer
Puja Umaretiya · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2023–2028 · cooperative agreement · U54
Radiation Oncology at the Interface of Pediatric Cancer Biology and Data Science
Daphne A. Haas-Kogan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · cooperative agreement · UH3
Single Molecule Detection of L1 Insertions and Intermediates
Bradley Evan Bernstein · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · research · R01
Regulatory mechanisms of mitochondrial cristae biogenesis and thermogenic function
Pere Puigserver · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · research · R01
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies
Constantine S. Mitsiades · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Probing the role of somatic X-chromosome alterations in shaping cancer sex differences
Srinivas Raghavan Viswanathan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Molecular mechanisms of splicing dependency in cohesin-mutant myelodysplasia
Zuzana Tothova · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinoma
Srinivas Raghavan Viswanathan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · career development · K00
Fertility legislation and unmet needs: Exploring intervenable barriers for quality oncofertility care among adolescent and young adult cancer patients
Julia Stal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · cooperative agreement · U01
Immunotherapeutic targeting of gangliosides in Ewing Sarcoma
Robbie G. Majzner · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Mitoribosome protein translation signaling and survival mechanisms
Pere Puigserver · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Consequences of retrotransposition on genome integrity
Kathleen H Burns · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2029 · career development · K00
Evaluating METTL1-mediated m7G tRNA methylation as a novel dependency in alveolar rhadomyosarcoma
Emma Anne Wilkinson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · career development · K08
Dissecting the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis for improved risk stratification and treatment
Riaz Gillani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma
Miguel Nicolas Rivera · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Clinical Trial Enrollment among Adolescents and Young Adults with Cancer
Jennifer W Mack · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2030 · research · R35
Targeting Pediatric Cancer Vulnerabilities
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2029 · career development · K00
BH3 Profiling in AML to Measure Apoptotic Signaling Kinetics of Approved Drugs and Identify Integrated Stress Response Apoptotic Susceptibilities
Johnson Ung · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Targeting SHP-1 through a newfound metabolite-regulated cysteine activation site
Edward Thomas Chouchani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · research · R01
Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer
Andrew James Aguirre · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · research · R01
Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies
Constantine S. Mitsiades · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · career development · K08
Improving response prediction to neoadjuvant therapy in pancreatic cancer
Harshabad Singh · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2026 · fellowship · F32
Targeting the cancer neo-genome for destruction with CRISPR-Cas enzymes
Mitchell L Leibowitz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · career development · K08
Harnessing the repetitive genome for cancer immunotherapy
Gabriel K. Griffin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · research · R01
Probing functional HIV-1 envelope glycoprotein conformations with novel potent CD4-mimetic compounds
Wayne A. Hendrickson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · research · R37
Acupuncture for Chemothrapy-induced Peripheral Neuropathy Treatment (ACT) Trial
Ting Bao · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · program · P50
DF/HCC Prostate SPORE
Steven P. Balk · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · career development · K23
Development and Pilot Testing of a Collaborative Agenda-Setting Intervention to Promote Patient-Centered Communication in Ovarian Cancer Care
Rachel Pozzar · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial
Alexi A Wright · Dana-Farber Cancer Institute · funded by National Institutes of Health
